UBM and Restec Announce End of Russia Affiliation
UBM and Restec end Russia affiliation, with Restec to hold a separate IPhEB exhibition in Russia starting in 2018.
UBM and Restec announced on August 1, 2017 that their joint effort in coordinating CPhI at the International Forum on Pharmaceuticals Engineering and Biotechnology (IPhEB) in Russia will end in 2018. The event, which held its 5th installment on March 30, 2017, will continue without the CPhl brand.
Having relocated from Saint Petersburg in 2011 to Moscow in 2015 with an increase of 5000 participants, the event will take place in its previous site and branding in 2018. Restec plans to continue serving the Russian market by moving forward alone with the IPhEB brand in Saint Petersburg in 2018 and Moscow in 2019.
UBM will focus on growing its international pharma influence, increasing sales reach within eight CPhI brands comprising of new events in Africa and the Middle East (Abu Dhabi) in 2018. Three additional functions will be held for CPhI Worldwide, CPhI India, and CPhI China, which total 40,000 participants collectively.
Source: CPhl
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
